Reference i literatura

Slika zaslona 2016-09-04 u 19.24.16


  1. Camp HS, Ren D, Leff T. Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol. Med.2002;8:442–447. [PubMed]

  2. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes. 2001;50:1612–1617.[PubMed]
  3. Kuhlmann J, et al. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes. 2003;52:138–144. [PubMed]
     
  4. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? [review] Int. J. Obes. Relat. Metab. Disord. 2003;27:147–161. [PubMed]
     
  5. Friedman JM. Obesity in the new millennium. Nature. 2000;404:632–634. [PubMed]
     
  6. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91. [PubMed]
     
  7. Hahn P. Cholesterol metabolism in obese mice. Can. J. Biochem. 1980;58:1258–1260. [PubMed]
     
  8. Boizard M, et al. Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors. J. Biol. Chem. 1998;273:29164–29171.[PubMed]
     
  9. Le Lay S, et al. Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J. Biol. Chem. 2001;276:16904–16910. [PubMed] 
  10. Dugail I, et al. New insights into how adipocytes sense their triglyceride stores. Is cholesterol a signal?Horm. Metab. Res. 2003;35:204–210. [PubMed]
     
  11. Guerre-Millo M, Guesnet P, Guichard C, Durand G, Lavau M. Alteration in membrane lipid order and composition in metabolically hyperactive fatty rat adipocytes. Lipids. 1994;29:205–209. [PubMed]
     
  12. Storch J, Shulman SL, Kleinfeld AM. Plasma membrane lipid order and composition during adipocyte differentiation of 3T3F442A cells. Studies in intact cells with 1-[4-(trimethylamino)phenyl]-6-phenylhexatriene. J. Biol. Chem. 1989;264:10527–10533. [PubMed]
     
  13. Kovanen PT, Nikkila EA, Miettinen TA. Regulation of cholesterol synthesis and storage in fat cells. J. Lipid Res. 1975;16:211–223. [PubMed]
     
  14. Schreibman PH, Dell RB. Human adipocyte cholesterol. Concentration, localization, synthesis, and turnover. J. Clin. Invest. 1975;55:986–993. [PMC free article] [PubMed]
     
  15. Pohl J, et al. Long-chain fatty acid uptake into adipocytes depends on lipid raft function. Biochemistry.2004;43:4179–4187. [PubMed]
     
  16. Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia. 1999;42:1033–1049. [PubMed]
     
  17. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 1994;79:1147–1156. [PubMed]
     
  18. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor γ (PPARγ): adipose predominant expression and induction early in adipocyte differentiation. Endocrinology.1994;135:798–800. [PubMed]
     
  19. Barak Y, et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell.1999;4:585–595. [PubMed]
     
  20. Rosen ED, et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell.1999;4:611–617. [PubMed]
     
  21. Horlein AJ, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995;377:397–404. [PubMed]
     
  22. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors.Nature. 1995;377:454–457. [PubMed]
     
  23. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors.Genes Dev. 2000;14:121–141. [PubMed]
     
  24. Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor γ (PPARγ) J. Biol. Chem. 1995;270:12953–12956. [PubMed]
     
  25. Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 1996;39:665–668. [PubMed]
     
  26. Berger J, et al. Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology.1996;137:4189–4195. [PubMed]
     
  27. Way JM, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology. 2001;142:1269–1277. [PubMed]
     
  28. de Souza CJ, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001;50:1863–1871. [PubMed]
     
  29. Chao L, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 2000;106:1221–1228. [PMC free article] [PubMed]
     
  30. Yamauchi T, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 2001;276:41245–41254. [PubMed]
     
  31. Li Y, Lazar MA. Differential gene regulation by PPARγ agonist and constitutively active PPARγ Mol. Endocrinol. 2002;16:1040–1048. [PubMed]
     
  32. Steppan CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312. [PubMed]
     
  33. Guan HP, et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med.2002;8:1122–1128. [PubMed]
     
  34. Banerjee RR, et al. Regulation of fasted blood glucose by resistin. Science. 2004;303:1195–1198.[PubMed]
     
  35. Tordjman J, et al. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells.J. Biol. Chem. 2003;278:18785–18790. [PubMed]
     
  36. Patsouris D, et al. PPARalpha governs glycerol metabolism. J. Clin. Invest. 2004;114:94–103. doi:10.1172/JCI200420468. [PMC free article] [PubMed]
     
  37. Sawamura T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–77. [PubMed]
     
  38. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 1992;41:393–398. [PubMed]
     
  39. Takamura T, Nohara E, Nagai Y, Kobayashi K. Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes. Eur. J. Pharmacol.2001;422:23–29. [PubMed]
     
  40. Moore KJ, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 2001;7:41–47. [PubMed]
     
  41. Nugent C, et al. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. Mol. Endocrinol. 2001;15:1729–1738. [PubMed]
     
  42. Camp HS, Chaudhry A, Leff T. A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology. 2001;142:3207–3213. [PubMed]
     
  43. Itabe H. Oxidized low-density lipoproteins: what is understood and what remains to be clarified [review]Biol. Pharm. Bull. 2003;26:1–9. [PubMed]
     
  44. Frohnert BI, Hui TY, Bernlohr DA. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J. Biol. Chem. 1999;274:3970–3977. [PubMed]
     
  45. Wyne KL. Free fatty acids and type 2 diabetes mellitus. Am. J. Med. 2003;115(Suppl. 8A):29S–36S.[PubMed]
     
  46. Rangwala SM, et al. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity.Dev. Cell. 2003;5:657–663. [PubMed]
     
  47. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol. Ther.2002;95:89–100. [PubMed]
     
  48. Tsimikas S, Witztum JL. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation. 2001;103:1930–1932. [PubMed]
     
  49. Ehara S, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–1960. [PubMed]
  50. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989;320:915–924. [PubMed]
     
  51. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation.1998;98:1487–1494. [PubMed]
     
  52. Berliner JA, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 1990;85:1260–1266. [PMC free article] [PubMed]
     
  53. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 1998;141:1–15. [PubMed]
     
  54. Navab M, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 1991;88:2039–2046. [PMC free article] [PubMed]
     
  55. Vora DK, et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ. Res. 1997;80:810–818. [PubMed]
     
  56. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 1999;103:1547–1560. [PMC free article][PubMed]
     
  57. Ling W, et al. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene. J. Clin. Invest. 1997;100:244–252.[PMC free article] [PubMed]
     
  58. Shoji T, et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis. 2000;148:171–177. [PubMed]
     
  59. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem. 1993;268:17665–17668. [PubMed]
     
  60. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 1994;269:21003–21009. [PubMed]
     
  61. Kuniyasu A, Hayashi S, Nakayama H. Adipocytes recognize and degrade oxidized low density lipoprotein through CD36. Biochem. Biophys. Res. Commun. 2002;295:319–323. [PubMed]
     
  62. Roberts AW, Thomas A, Rees A, Evans M. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr. Opin. Lipidol. 2003;14:567–573. [PubMed]
     
  63. Gilling L, Suwattee P, DeSouza C, Asnani S, Fonseca V. Effects of the thiazolidinediones on cardiovascular risk factors. Am. J. Cardiovasc. Drugs. 2002;2:149–156. [PubMed]
     
  64. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol. 2003;42:1757–1763. [PubMed]
     
  65. Li AC, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2000;106:523–531. [PMC free article][PubMed]
    66. Chen Z, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 2001;21:372–377. [PubMed]
     
  66. Chawla A, et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 2001;7:161–171. [PubMed]
     
  67. Li AC, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 2004;114:1564–1576. doi:10.1172/JCI200418730.[PMC free article] [PubMed]
     
  68. Chiba Y, Ogita T, Ando K, Fujita T. PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. Biochem. Biophys. Res. Commun. 2001;286:541–546. [PubMed]
     
  69. Armoni M, et al. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J. Biol. Chem. 2003;278:30614–30623.[PubMed]
     
  70. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 2005;19:453–461. [PMC free article] [PubMed]
     
  71. Gavrilova O, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003;278:34268–34276.[PubMed]
     
  72. Hevener AL, et al. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 2003;9:1491–1497. [PubMed]
     
  73. Norris AW, et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 2003;112:608–618. doi:10.1172/JCI200317305.[PMC free article] [PubMed]
     
  74. Cock TA, Houten SM, Auwerx J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm [review] EMBO Rep. 2004;5:142–147. [PMC free article] [PubMed]
     
  75. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors [review] Endocrinology. 2003;144:2201–2207. [PubMed]
     
  76. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.Trends Pharmacol. Sci. 2004;25:331–336. [PubMed]
     
  77. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:1–10. [PubMed]
     
  78. Danforth E., Jr Failure of adipocyte differentiation causes type II diabetes mellitus? [letter] Nat. Genet.2000;26:13. [PubMed]
     
  79. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med.2003;115(Suppl. 8A):42S–48S. [PubMed]
     
  80. Okuno A, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 1998;101:1354–1361. [PMC free article] [PubMed]
     
  81. Wilson-Fritch L, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J. Clin. Invest. 2004;114:1281–1289. doi:10.1172/JCI200421752. [PMC free article][PubMed]
     
  82. Ye JM, et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia. 2004;47:1306–1313. [PubMed]
     
  83. Chawla A, Lazar MA. Peroxisome proliferator and retinoid signalling pathways coregulate preadipocyte phenotype and survival. Proc. Natl. Acad. Sci. U. S. A. 1994;91:1786–1790. [PMC free article] [PubMed]
     
  84. Hartman HB, Hu X, Tyler KX, Dalal CK, Lazar MA. Mechanisms regulating adipocyte expression of resistin. J. Biol. Chem. 2002;277:19754–19761. [PubMed]
     
  85. Orlicky DJ, Schaack J. Adenovirus transduction of 3T3-L1 cells. J. Lipid Res. 2001;42:460–466.[PubMed]
  86. The phisiological Medical Letter Vol.3 Nr.1 Settembre 2010 Alfenas Rde C, Bressan J, de Paiva AC. Effects of protein quality on appetite and energy metabolism in normal weight subjects. Arq Bras Endocrinol Metabol. 2010 Feb;54(1):45-51.
  87. Blackburn G.L., Benefits of weight loss in the treatment of obesity. Am J Clin Nutr. 1999 Mar; 69 (3) : 347-9.
  88. Blackburn G.L., Functional foods in the prevention and treatment of disease: significance of the Dietary Approaches to Stop Hypertension Study. Am J Clin Nutr. 1997 Nov;66(5):1067-71
  89. Blackburn G.L., More on the obesity problem. N Engl J Med. 1998 Jun 4;338(23):1702
  90. Blackburn G.L., Pharmaceutical treatment of obesity. Nurs Clin North Am. 1997
  91. Carstens GE, Effects of bovine somatotropin treatment and intermittent growth pattern on mammary gland development in heifers. J Anim Sci 75(9), 2378-2388 (1997)
  92. Clark RG, Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology 138(10), 4316-4323 (1997)
  93. Esfahani A, Wong JM, Mirrahimi A, Srichaikul K, Jenkins DJ, Kendall CW. The glycemic index: physiological significance. J Am Coll Nutr. 2009 Aug;28 Suppl:439S-445S. Review.
  94. Ferranini E Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100(5), 1166-1173 (1997)
  95. French SA, Sex differences among participants in a weight-control program. Addict Behav 19(2), 147-158 (1994)
  96. Janjic D Android-type obesity and gynecoid-type obesityÍ (Schweiz Rundsch Med Prax, 1996 Dec 3)
  97. Jørgensen JO, Rubeck KZ, Nielsen TS, Clasen BF, Vendelboe M, Hafstrøm TK, Madsen M, Lund S. Effects of GH in human muscle and fat. Pediatr Nephrol. 2010 Apr;25(4):705-9. Epub 2009 Nov 10.
  98. Kopelman PG Hormones and obesity. (Baillieres Clin Endocrinol Metab, 1994 Jul) Lauterio TJ Growth hormone secretion and synthesis are depressed in obesity-susceptible compared with obesity-resistant rats. (Metabolism, 1997 Feb)
  99. Loftus T.M., Lane, Modulating the trascriptional control of adipogenesis – Current opinion in Genetics & Development – 1997, 7: 603 – 608
  100. Mattson MP. Perspective: Does brown fat protect against diseases of aging? Ageing Res Rev. 2010 Jan;9(1):69-76. Epub 2009 Dec 5. Review.
  101. Mauriege P, Regional differences in adipose tissue metabolism between sedentary and endurance-trained women. Am J Physiol 273(3), E497-E506 (1997)
  102. Moller N, Vendelbo MH, Kampmann U, Christensen B, Madsen M, Norrelund H, Jorgensen JO. Growth hormone and protein metabolism. Clin Nutr. 2009 Dec;28(6):597-603. Epub 2009 Sep 20. Review.
    Rasmussen MH. Obesity, growth hormone and weight loss. Mol Cell Endocrinol. 2010 Mar 25;316(2):147-53. Epub 2009 Aug 31. Review
  103. Westerterp-Plantenga MS, Nieuwenhuizen A, Tomé D, Soenen S, Westerterp KR Dietary protein, weight loss, and weight maintenance. Annu Rev Nutr. 2009;29:21-41. Review.
  104. York B Sensitivity to dietary obesity linked to a locus on chromosome 15 in a CAST/Ei x C57BL/6J F2 intercross. (Mamm Genome, 1996 Se
  105. Shen L, Kenan M, Raggio A, Williams C, Martin RJ (October 2011). “Dietary-resistant starch improves maternal glycemic control in Goto-Kakizaki rat”. Mol Nutr Food Res. 55 (10): 1499–508. doi:1002/mnfr.201000605. PMID 21638778. Retrieved 2014-07-17.
  106. “Weight Loss: High-Protein, Low-Carbohydrate Diets”. Women.webmd.com. Retrieved 2011-12-18.
  107. Hanlon, ^athie: The Low-Down on Low-Carbohydrate Diets, Vanderbuilt University, 25 April 1997
  108. Dolson, Laura: What is a Low Carb Diet?, About.com: Low Carb Diets, retrieved 11 March 2008
  109. Naude, CE; Schoonees, A; Senekal, M; Young, T; Garner, P; Volmink, J (2014). “Low carbohydrate versus isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review and meta-analysis.”. PLOS ONE. 9 (7): e100652. doi:1371/journal.pone.0100652. PMID 25007189.
  110. Low Carb Dietco.uk: Low carb diet, retrieved 9 August 2011
  111. Diabetes Group Backs Low-Carb Diets, HealthDay News on S. News and World Report, 28 December 2007
  112. Taubes, Gary (2011). Why We Get Fat: And What to Do About It. New York: Anchor Books. pp. 164–167. ISBN 978-0-307-59551-5.
  113. Richards, M. P. (2002). “A brief review of the archaeological evidence for Palaeolithic and Neolithic subsistence”. European Journal of Clinical Nutrition. 56(12): 1270–1278. doi:1038/sj.ejcn.1601646. PMID 12494313.
  114. Fiorenza, L.; Benazzi, S.; Tausch, J.; Kullmer, O.; Bromage, T. G.; Schrenk, F. (2011). Rosenberg, Karen, ed. “Molar Macrowear Reveals Neanderthal Eco-Geographic Dietary Variation”. PLoS ONE. 6 (3): e14769.doi:1371/journal.pone.0014769. PMC 3060801. PMID 21445243.
  115. Cordain, L.; Miller, J. B.; Eaton, S. B.; Mann, N.; Holt, S. H.; Speth, J. D. (2000). “Plant-animal subsistence ratios and macronutrient energy estimations in worldwide hunter-gatherer diets”. The American Journal of Clinical Nutrition. 71 (3): 682–692.PMID 10702160.
  116. Milton, K. (2000). “Hunter-gatherer diets-a different perspective”. The American Journal of Clinical Nutrition. 71 (3): 665–667. PMID 10702155.
  117. Milton, Katharine (2002). “Hunter-gatherer diets: wild foods signal relief from diseases of affluence (PDF)” (PDF). In Ungar, Peter S.; Teaford, Mark F. Human Diet: Its Origins and Evolution. Westport, CT: Bergin and Garvey. pp. 111–22. ISBN 0-89789-736-6.
  118. Cordain, Loren (2007). “Implications of Plio-Pleistocene Hominin Diets for Modern Humans (PDF)” (PDF). In Ungar, Peter S. Early Hominin Diets: The Known, the Unknown, and the Unknowable. Oxford, USA: Oxford University Press. pp. 363–83.ISBN 0-19-518347-9.
  119. Morgan, William (1877). Diabetes mellitus: its history, chemistry, anatomy, pathology, physiology, and treatment.
  120. Einhorn, Max (1905). Lectures on dietetics.
  121. William Banting (1869). Letter On Corpulence, Addressed to the Public (4th ed.). London, England: Harrison. Retrieved 2008-01-02.
  122. Barry Groves (2002). “William Banting Father of the Low-Carbohydrate Diet”. TheWeston A. Price Foundation.
  123. 1967: the Stillman diet – History Of Diets, Part 12 – protein diet Men’s Fitness. June 2003
  124. Air Force Diet. Toronto, Canada, Air Force Diet Publishers, 1960.
  125. Gardner Jameson and Elliot Williams (1964) The Drinking Man’s Diet. San Francisco: Cameron. (2004) Revised Ed. ISBN 978-0-918684-65-3. See also Alan Farnham (2004) “The Drinking Man’s Diet”, Forbes.com.
  126. Lutz, Wolfgang; Allan, C.B. Life Without Bread. McGraw-Hill; 2000. ISBN 978-0-658-00170-3. English language, 1st Ed.
  127. Gordon, Edgar; Goldberg, Marshall; Chosy, Grace (October 1963). “A New Concept in the Treatment of Obesity”. JAMA. 186 (1): 50–60.doi:1001/jama.1963.63710010013014. Retrieved 19 January 2015.
  128. A critique of low-carbohydrate ketogenic weight reduction regimens. A review of Dr. Atkins’ diet revolution., Journal of the American Medical Association, 1973
  129. Voegtlin, Walter L. (1975). The stone age diet: Based on in-depth studies of human ecology and the diet of man. Vantage Press. ISBN 0-533-01314-3.
  130. Jenkins, DJ; Wolever, TM; Taylor, RH; Barker, H; Fielden, H; Baldwin, JM; Bowling, AC; Newman, HC; et al. (1981). “Glycemic index of foods: A physiological basis for carbohydrate exchange”. The American Journal of Clinical Nutrition. 34 (3): 362–6.PMID 6259925.
  131. “PBS News Hour: Low Carb Craze”. Pbs.org. Retrieved 2011-12-18.
  132. Americans Look for Health on the Menu: Survey finds nutrition plays increasing role in dining-out choices [1]
  133. Morning Edition (22 June 2004). “Low-Carb Diets Trim Krispy Kreme’s Profit Line”. Npr.org. Retrieved 2011-12-18.
  134. Jeor, Sachiko T., RD, PhD; Howard, Barbara V., PhD; Prewitt, T. Elaine, RD, DrPH; Bovee, Vicki, RD, MS; Bazzarre, Terry, PhD; Eckel, Robert H., MD (2001).”Dietary Protein and Weight Reduction: A Statement for Healthcare Professionals From the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association” (Science Advisory). American Heart Association. Retrieved March 1, 2014. These diets are generally associated with higher intakes of total fat, saturated fat, and cholesterol because the protein is provided mainly by animal sources. … Beneficial effects on blood lipids and insulin resistance are due to the weight loss, not to the change in caloric composition. … High-protein diets may also be associated with increased risk for coronary heart disease due to intakes of saturated fat, cholesterol, and other associated dietary factors.
  135. The American Kidney Fund: American Kidney Fund Warns About Impact of High-Protein Diets on Kidney Health: 25 April 2002
  136. BBC (19 January 2004) Atkins diet boss: ‘Eat less fat’. BBC News. Retrieved on 12 September 2007.
  137. The Atkins Essentials: A Two-Week Program to Jump-start Your Low Carb Lifestyle, ISBN 978-0-06-059838-9, page 23
  138. Sears, Barry; Lawren, Bill: Enter the Zone, Regan Books, 1995, 352 pp, ISBN 0-06-039150-2
  139. Brand-Miller, Jennie; Foster-Powell, Kaye; McMillan-Price, Joanna: The Low GI Diet Revolution: The Definitive Science-Based Weight Loss Plan, Marlowe & Company, 30 November 2004, 336 pp, ISBN 978-1-56924-413-5
  140. Kossoff, Eric: Do ketogenic diets work for adults with epilepsy? Yes!, Epilepsy.com, updated 22 February 2008
  141. Rosen, Evan David: Weighing In On the Low Carb Diet Controversy, Defeat Diabetes Foundation, 18 June 2003
  142. Burros, Marian (21 January 2004). “Eating Well; The Post-Atkins Low Carb Diet”.The New York Times. Retrieved 19 December 2010.
  143. “The Paleo Diet Simplified – The Three Food Groups to Avoid”. Better Mind Body Soul.
  144. ^Lydia A. Bazzano; Tian Hu, Kristi Reynolds; et al. (2 September 2014). “Effects of Low-Carbohydrate and Low-Fat Diets: A Randomized Trial”. Annals of Internal Medicine. 16 (5): 309–318. doi:7326/M14-0180. Retrieved 1 February 2015.(subscription required)
  145. ^ANAHAD O’CONNOR (Sep 1, 2014). “A Call for a Low-Carb Diet That Embraces Fat”. New York Times. Retrieved 1 February 2015.
  146. ^  to:ab c Position Statement on Very Low Carbohydrate Diets, Heart Foundation, retrieved 19 July 2008. It states
  147. Based on current available evidence, the Heart Foundation does not support the adoption of VLCARB diets for weight loss.
  148. The Heart Foundation found that subjects in research studies achieved more weight and fat loss on the VLCARB diets than on the conventional low fat diets, but this was only in the short term.
  149. The Heart Foundation’s major concern with many VLCARB [Very Low Carb] diets is not their restriction of carbohydrate or increase in protein, but their high and unrestricted saturated fat content, which may contribute to cardiovascular risk.
  150. ^Last AR, Wilson SA (June 2006). “Low-carbohydrate diets”. American Family Physician. 73 (11): 1942–8. PMID 16770923.
  151. ^Ann Louise Gittleman: Eat Fat, Lose Weight, Chapter 5, McGraw Hill, 11 March 1999, ISBN 0-87983-966-X / 9780879839666
  152. ^Eades, Michael R.; Eades, Mary Dan: Protein Power, Chapter 1, Bantam Books, 1999, ISBN 0-553-38078-8
  153. ^Normal Regulation of Blood Glucose, EndocrineWeb.com, retrieved 12 March 2008
  154. ^Dolson, Laura: What Are Net Carbs?, About.com: Low Carb Diets, retrieved 13 March 2008
  155. ^”BREAKTHROUGH SCIENCE ADVANCES ATKINS LABELING CLAIMS ON FOOD PRODUCTS” (Press release). New York, New York: atkins.com. 6 October 2004. Archived from the original on 28 October 2014.
  156. ^[2], Carbstation.com, retrieved 25 January 2011
  157. ^”Dietary Reference Intakes (DRIs):” (PDF). National Academy of Medicine. Retrieved 2015-08-31.
  158. ^Food and Nutrition Board (2002/2005). Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: The National Academies Press. Page 769. ISBN 0-309-08537-3
  159. ^Joint WHO/FAO expert consultation (2003). “Diet, Nutrition and the Prevention of Chronic Diseases” (PDF). who.int. Geneva: World Health Organization. pp. 55–56.ISBN 92-4-120916-X. Archived from the original (PDF) on 4 April 2003.
  160. ^Yancy WS, Foy M, Chalecki AM, Vernon MC, Westman EC (2005). “A low-carbohydrate, ketogenic diet to treat type 2 diabetes”. Nutrition & Metabolism. 2 (1): 34. doi:1186/1743-7075-2-34. PMC 1325029. PMID 16318637.
  161. ^John M. Freeman, Eric H. Kossoff, Jennifer B. Freeman, Millicent T. Kelly: The Ketogenic Diet: A Treatment for Children and Others with Epilepsy, 4th edition, Demos Medical Publishing, 4 October 2006, ISBN 978-1-932603-18-7
  162. ^Michael R. Eades , Mary Dan Eades, The Protein Power Lifeplan, Warner Books, 2000, ISBN 0-446-52576-6
  163. ^Lick the Sugar Habit: How to Break Your Sugar Addiction Naturally, second edition, Avery, 1 February 1988, ISBN 978-0-89529-768-6
  164. ^Cancer Loves Sugar, Wellness Directory of Minnesota, retrieved 22 July 2008
  165. ^Taubes, Gary. GOOD CALORIES, BAD CALORIES. Anchor Books.ISBN 9781400033461.
  166. ^Brand-Miller et al. (2005). The Low GI Diet Revolution: The Definitive Science-based Weight Loss Plan. Marlowe & Company. New York, NY
  167. ^”The Glycemic Index debate: Does the type of carbohydrate really matter? – All About Diabetes – American Diabetes Association”. 2007-02-14. Archived from the original on 14 February 2007. Retrieved 2015-11-16.
  168. ^SH Holt; JC Miller; P Petocz (1 November 1997). “An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods”. American Journal of Clinical Nutrition. 66 (5): 1264–1276. PMID 9356547.
  169. ^High-Protein Diets, American Heart Association, 14 March 2008
  170. ^Weighing In on Low-Carb Diets, The American Cancer Society
  171. ^Karra, Cindy: Shape Up America! Reveals The Truth About Dieters, Shape Up America! (by former U.S. Surgeon General C. Everett Koop), 29 December 2003
  172. ^Gasior, M; Rogawski, MA; Hartman, AL (2006). “Neuroprotective and disease-modifying effects of the ketogenic diet”. Behavioural Pharmacology. 17 (5–6): 431–9. doi:1097/00008877-200609000-00009. PMC 2367001. PMID 16940764.
  173. ^Hartman AL, Vining EP (January 2007). “Clinical aspects of the ketogenic diet”.Epilepsia. 48 (1): 31–42. doi:1111/j.1528-1167.2007.00914.x. PMID 17241206.
  174. ^Delbridge E, Proietto J (2006). “State of the science: VLED (Very Low Energy Diet) for obesity”. Asia Pacific Journal of Clinical Nutrition. 15 Suppl: 49–54.PMID 16928661.
  175. ^Carr, Timothy P.: Discovering Nutrition, Chapter 7, Blackwell Publishing, October 2002, ISBN 978-0-632-04564-8
  176. ^Eades, Michael R. (19 September 2006). “Protein Power verses Intermittent Fasting”. proteinpower.com. Retrieved 19 December 2010.
  177. ^Morrison, Katharine (February 2005). “Dietary Carbohydrate, Protein and Fat for People With Glucose Metabolism Disorders. Just What is Optimal?”. D-Solve: Low Carb & Low Insulin Diabetes Management.
  178. ^Dolson, Laura: What is Ketosis?, About.com: Low Carb Diets, retrieved 13 March 2008
  179. ^Bowen, R.: The Endocrine Pancreas, Colorado State University: Hypertexts for Biomedical Sciences, 8 December 2002
  180. ^Grieb, P; Kłapcińska, B; Smol, E; Pilis, T; Pilis, W; Sadowska-Krepa, E; Sobczak, A; Bartoszewicz, Z; et al. (2008). “Long-term consumption of a carbohydrate-restricted diet does not induce deleterious metabolic effects”. Nutrition research. 28 (12): 825–33. doi:1016/j.nutres.2008.09.011. PMID 19083495.
  181. ^Arizona State University (17 December 2007). Researchers Nix Low-carb Diet. ScienceDaily. Retrieved 15 April 2011, fromhttp://www.sciencedaily.com/releases/2007/12/071217150506.htm
  182. ^Clinical use of a Carbohydrate-Restricted Diet to Treat the Dyslipidemia of the Metabolic Syndrome [3]
  183. ^Taubes, Gary: What if It’s All Been a Big Fat Lie?, New York Times, Friday, 15 February 2008
  184. ^Kekwick A, Pawan GL (July 1956). “Calorie intake in relation to body-weight changes in the obese”. Lancet. 271 (6935): 155–61. doi:1016/S0140-6736(56)91691-9. PMID 13347103.
  185. ^  to:ab c Shai, Iris; Schwarzfuchs, Dan; Henkin, Yaakov; Shahar, Danit R.; Witkow, Shula; Greenberg, Ilana; Golan, Rachel; Fraser, Drora; et al. (2008). “Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet”. New England Journal of Medicine. 359 (3): 229–41. doi:1056/NEJMoa0708681. PMID 18635428.
  186. ^Stern, L; Iqbal, N; Seshadri, P; Chicano, KL; Daily, DA; McGrory, J; Williams, M; Gracely, EJ; Samaha, FF (2004). “The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial”. Annals of Internal Medicine. 140 (10): 778–85. doi:7326/0003-4819-140-10-200405180-00007. PMID 15148064.
  187. ^Astrup, Arne; Larsen, Thomas Meinert; Harper, Angela (2004). “Atkins and other low-carbohydrate diets: Hoax or an effective tool for weight loss?”. The Lancet. 364(9437): 897–9. doi:1016/S0140-6736(04)16986-9. PMID 15351198.
  188. ^Johnston, CS; Tjonn, SL; Swan, PD; White, A; Hutchins, H; Sears, B (2006).”Ketogenic low-carbohydrate diets have no metabolic advantage over nonketogenic low-carbohydrate diets”. The American Journal of Clinical Nutrition. 83 (5): 1055–61. PMID 16685046.
  189. ^Kappagoda, C.Tissa; Hyson, Dianne A.; Amsterdam, Ezra A. (2004). “Low-carbohydrate–high-protein diets”. Journal of the American College of Cardiology. 43(5): 725–30. doi:1016/j.jacc.2003.06.022. PMID 14998607.
  190. ^Charlotte E. Grayson, M.D., Protein Diet: An Effective Way to Lose Weight, TheHealthGuide
  191. ^Halton, Thomas L.; Willett, Walter C.; Liu, Simin; Manson, Joann E.; Albert, Christine M.; Rexrode, Kathryn; Hu, Frank B. (2006). “Low-Carbohydrate-Diet Score and the Risk of Coronary Heart Disease in Women”. New England Journal of Medicine. 355 (19): 1991–2002. doi:1056/NEJMoa055317. PMID 17093250.
  192. ^  to:ab Gardner, Christopher D.; Kiazand, A.; Alhassan, S.; Kim, S.; Stafford, R. S.; Balise, R. R.; Kraemer, H. C.; King, A. C. (2007). “Comparison of the Atkins, Zone, Ornish, and LEARN Diets for Change in Weight and Related Risk Factors Among Overweight Premenopausal Women<SUBTITLE>The a TO Z Weight Loss Study: A Randomized Trial</SUBTITLE>”. JAMA: the Journal of the American Medical Association. 297 (9): 969–77. doi:1001/jama.297.9.969. PMID 17341711.
  193. ^Nielsen, Jørgen; Joensson, Eva (2006). “Low-carbohydrate diet in type 2 diabetes. Stable improvement of bodyweight and glycemic control during 22 months follow-up”. Nutrition & Metabolism. 3: 22. doi:1186/1743-7075-3-22. PMC 1526736.PMID 16774674.
  194. ^Grieb, Paweł; Kłapcińska, Barbara; Smol, Ewelina; Pilis, Tomasz; Pilis, Wiesław; Sadowska-Krępa, Ewa; Sobczak, Andrzej; Bartoszewicz, Zbigniew; et al. (2008). “Long-term consumption of a carbohydrate-restricted diet does not induce deleterious metabolic effects”. Nutrition Research. 28 (12): 825–33.doi:1016/j.nutres.2008.09.011. PMID 19083495.
  195. ^Samaha, Frederick F.; Iqbal, Nayyar; Seshadri, Prakash; Chicano, Kathryn L.; Daily, Denise A.; McGrory, Joyce; Williams, Terrence; Williams, Monica; et al. (2003). “A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity”. New England Journal of Medicine. 348 (21): 2074–81. doi:1056/NEJMoa022637.PMID 12761364.
  196. ^Foster, Gary D.; Wyatt, Holly R.; Hill, James O.; McGuckin, Brian G.; Brill, Carrie; Mohammed, B. Selma; Szapary, Philippe O.; Rader, Daniel J.; et al. (2003). “A Randomized Trial of a Low-Carbohydrate Diet for Obesity”. New England Journal of Medicine. 348 (21): 2082–90. doi:1056/NEJMoa022207. PMID 12761365.
  197. ^Dansinger, M. L.; Gleason, JA; Griffith, JL; Selker, HP; Schaefer, EJ (2005). “Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk Reduction: A Randomized Trial”. JAMA: the Journal of the American Medical Association. 293 (1): 43–53. doi:1001/jama.293.1.43.PMID 15632335.
  198. ^Merchant, Anwar T.; Vatanparast, Hassanali; Barlas, Shahzaib; Dehghan, Mahshid; Shah, Syed Mahboob Ali; De Koning, Lawrence; Steck, Susan E. (2009).”Carbohydrate Intake and Overweight and Obesity among Healthy Adults”. Journal of the American Dietetic Association. 109 (7): 1165–72.doi:1016/j.jada.2009.04.002. PMC 3093919. PMID 19559132.
  199. ^Bueno, Nassib B. (2013). “Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials.”. British Journal of Nutrition. 110: 1178–1187. doi:1017/S0007114513000548.
  200. ^”Corrections to News item on carbohydrate, fat and obesity”. 2013-11-27.
  201. ^Weigle, DS; Breen, PA; Matthys, CC; Callahan, HS; Meeuws, KE; Burden, VR; Purnell, JQ (2005). “A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight despite compensatory changes in diurnal plasma leptin and ghrelin concentrations”. The American Journal of Clinical Nutrition.82 (1): 41–8. PMID 16002798.
  202. ^Westman EC, Feinman RD, Mavropoulos JC, Vernon MC, Volek JS, Wortman JA, Yancy WS, Phinney SD (1 August 2007). “Low-carbohydrate nutrition and metabolism”. The American Journal of Clinical Nutrition. 86 (2): 276–84.PMID 17684196.
  203. ^Colagiuri, Stephen; & Brand-Miller, Jennie (March 2002). “The ‘carnivore connection’—evolutionary aspects of insulin resistance” (PDF). European Journal of Clinical Nutrition. 56 (1): S30–5. doi:1038/sj.ejcn.1601351. PMID 11965520.
  204. ^Kopp, Wolfgang (May 2006). “The atherogenic potential of dietary carbohydrate”.Preventive Medicine. 42 (5): 336–42. doi:1016/j.ypmed.2006.02.003.PMID 16540158.
  205. ^Hu, T; Mills, KT; Yao, L; Demanelis, K; Yancy Jr, WS; Kelly, TN; He, J; Bazzano, LA (2010). “Effects of Low-Carbohydrate Diets Versus Low-Fat Diets on Metabolic Risk Factors: A Meta-Analysis of Randomized Controlled Clinical Trials”. American Journal of Epidemiology. 176 (Suppl 7): S44–S54. doi:1093/aje/kws264.PMID 23035144.
  206. ^Hession, M.; Rolland, C.; Kulkarni, U.; Wise, A.; Broom, J. (2009). “Systematic review of randomized controlled trials of low-carbohydrate vs. Low-fat/low-calorie diets in the management of obesity and its comorbidities”. Obesity Reviews. 10 (1): 36–50.doi:1111/j.1467-789X.2008.00518.x. PMID 18700873.
  207. ^  to:ab Fung, TT; Van Dam, RM; Hankinson, SE; Stampfer, M; Willett, WC; Hu, FB (2010). “Low-carbohydrate diets and all-cause and cause-specific mortality: Two cohort studies”. Annals of Internal Medicine. 153 (5): 289–98. doi:1059/0003-4819-153-5-201009070-00003. PMC 2989112. PMID 20820038.
  208. ^Salvini, Simonetta; Hunter, David J; Sampson, Laura; Stampfer, Meir J; Colditz, Graham A; Rosner, Bernard; Willett, Walter C (1989). “Food-Based Validation of a Dietary Questionnaire: The Effects of Week-to-Week Variation in Food Consumption”.International Journal of Epidemiology. 18 (4): 858–67. doi:1093/ije/18.4.858.PMID 2621022.
  209. ^Minger, Denise. “Brand-Spankin’ New Study: Are Low-Carb Meat Eaters in Trouble?”. Raw Food SOS. Retrieved 15 May 2011.
  210. ^Kirby, Rebecca K. (1 June 2006). “Low-Carbohydrate Dieting”. American Family Physician. American Academy of Family Physicians. 73 (11): 1896–1901. Retrieved12 February 2014. The paper states :… a major problem with them is that many persons attempting to follow a low-carbohydrate regimen do not eat a variety of fruits and vegetables … :… :A low dietary glycemic load also has been shown to reduce the risk of cardiovascular disease and the risk of developing type 2 diabetes. :… :Normal kidney function does not seem to preclude a high-protein diet, but the long-term effects on bone status are unclear. :… :Because of our diverse health requirements and inherent biochemical individuality, some people will do better on low-fat diets and some people will do better on low-carb diets.
  211. ^”Nutrition Recommendations and Interventions for Diabetes”. Diabetes Care. American Diabetes Association. 31: S61–S78. January 2008. doi:2337/dc08-s061. Retrieved 12 February 2014. :For weight loss, either low-carbohydrate or low-fat calorie-restricted diets may be effective in the short term (up to 1-year).
  212. ^Christine Many Luff (March 2008). “American Diabetes Association Backs Low-Carb Diets”. dlife.com. Retrieved 12 February 2014.
  213. ^”Diabetes Group Backs Low-Carb Diets”. S. News & World Report. 28 December 2007
  214. ^Patrick Totty, “ADA Now Supports Low-Carb Diets”. Diabetes Health. 9 January 2008
  215. ^”ADA 2009 Recommendations Reaffirm Acceptance of Low Carb Diet”. 29 December 2008. Retrieved 19 December 2010.
  216. ^American Dietetic Association Says New Studies of Low-Carb Diets “Confirm What We Already Know – There Is No Magic Bullet to Safe and Healthful Weight Loss’
  217. ^Question of the Day – Do Carbohydrates Cause Weight Gain?
  218. ^[4], American Heart Association, 18 July 2008. It states
  219. The American Heart Association doesn’t recommend high-protein diets for weight loss. Some of these diets restrict healthful foods that provide essential nutrients and don’t provide the variety of foods needed to adequately meet nutritional needs. People who stay on these diets very long may not get enough vitamins and minerals and face other potential health risks.
  220. ^Stobbe, Mike. “Study: Low-carb diet best for weight, cholesterol.” The Seattle Times. 17 July 2008
  221. ^Starchy foods, National Health Service, retrieved 5 December 2013. It states
  222. Low-carbohydrate (low-carb) diets usually involve cutting out most starchy foods. These diets tend to be high in fat, and eating a high-fat diet (especially saturated fat from foods such as meat, cheese, and butter) could increase your risk of heart disease. Low-carb diets could also restrict the amount of fruit, vegetables, and fibre you eat, so try to ensure starchy foods make up about a third of your diet.
  223. ^Må bättre med lågkolhydratkost, e-Health.se, 28 April 2008 Archived 2 May 2008 at the Wayback Machine.
  224. ^[5]
  225. ^Your Guide to a Healthy Heart, U.S. Department of Health and Human Services, December 2005. It states
  226. … they’re not the route to healthy, long-term weight management. A diet high in fat, especially if it is high in saturated fat, is not good for your heart. These diets are also high in protein and can cause kidney problems and increased bone loss. High-fat, low-carb diets are also low in many essential vitamins, minerals, and fiber.
  227. ^Low Carb – US – May 2004, The InfoShop.com by Global Markets, 2004.
  228. ^ZERNIKE, KATE; BURROS, MARIAN: Low-Carb Boom Isn’t Just for Dieters Anymore, New York Times, February 19, 2004.
  229. ^History of the Dr. Atkins Diet Plan, Atkins Diet Advisor. Retrieved 10 March 2008.
  230. ^WARNER, MELANIE: Is the Low-Carb Boom Over?, New York Times, 5 December 2004.
  231. ^Low-Carb Diet Effective for Teens Trying to Lose Weight, Cincinnati Children’s Hospital, 6 May 2007.
  232. ^Bernstein, Richard: Why the Low Carb Diet is Best, Diabetes Health, 24 April 2007.
  233. ^Warshaw, Hope: [6], Diabetes Health, 24 April 2007.
  234. ^Karra, Cindy: Shape Up America! Reveals The Truth About Dieters, Shape Up America! (by former U.S. Surgeon General C. Everett Koop), 29 December 2003.
  235. ^ADA Issues New Clinical Practice Recommendations, Bio-Medicine, 28 December 2007, Alexandria, VA.
  236. ^Exclusive Interview: Dr. Annika Dahlqvist Gets Swedish Government To Promote Livin’ La Vida Low-Carb! (Episode 107), The Livin La Vida Low-Carb Show, 28 January 2008
  237. ^Fogoros, Richard N.: Low Fats, or Low Carbs?, About.com: Heart Disease, February 2006.
  238. ^  to:ab Warner, Jennifer: Jury Still Out on Low-Carbohydrate Diets, WebMD.com, April 8, 2003.
  239. ^Mendosa, David: The Carb Controversy, HealthCentral.com: Diabetes, 1 March 2006.
  240. ^Low-Carb Experts Drs. Michael and Mary Dan Eades Offer Rebuttal to Recent ‘Report’ Suggesting Low Carb Diets Are Unhealthy According to LowCarbiz, Business Wire, 26 November 2003.
  241. ^AtkinsExposed: References 1 – 1160, AtkinsExposed.org. Retrieved 12 March 2008.
  242. ^Research Supporting a Low-Carb Diet, Wilstar. Retrieved 12 March 2008.
  243. ^BURROS, MARIAN: EATING WELL; The Post-Atkins Low Carb Diet, The New York Times, 21 January 2004.
  244. ^Low Carbohydrate – How Do Low Carb Diets Work?, WeightLossResources.co.uk. Retrieved 12 March 2008.
  245. ^Santos, F. L., Esteves, S. S., da Costa Pereira, A., Yancy, W. S. and Nunes, J. P. L. (2008-08-12). “Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors”. Obesity Reviews. 13: 1048–1066. doi:1111/j.1467-789X.2012.01021.x.
  246. ^Ajala O.; English P.; Pinkney J. (2013). “Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes”. The American Journal of Clinical Nutrition. 97 (3): 505–516. doi:3945/ajcn.112.042457.
  247. ^Freedman MR, King J, and Kennedy E (2001), Popular Diets: a Scientific ReviewObesity Research, Volume 9, Supplement 1, Pages 1S-5S. Retrieved on 15 August 2013.
  248. ^  to:ab Eades, M. (1995) The Protein Power Lifeplan, Warner Books. ISBN 0-446-67867-8[page needed]
  249. ^Kang, Hoon Chul; Chung, Da Eun; Kim, Dong Wook; Kim, Heung Dong (2004). “Early- and Late-onset Complications of the Ketogenic Diet for Intractable Epilepsy”.Epilepsia. 45 (9): 1116–23. doi:1111/j.0013-9580.2004.10004.x.PMID 15329077.
  250. ^  to:ab Phinney SD (2004). “Ketogenic diets and physical performance”. Nutrition & Metabolism. 1 (1): 2. doi:1186/1743-7075-1-2. PMC 524027.PMID 15507148.
  251. ^  to:ab Phinney, Stephen (2004). “Ketogenic diets and physical performance”.Nutrition and Metabolism. 1 (1): 2. doi:1186/1743-7075-1-2. PMC 524027.PMID 15507148.
  252. ^Peter Heinbecker (1928). “Studies on the Metabolism of Eskimos” (PDF). J. Biol. Chem. 80 (2): 461–475. Retrieved 2014-04-07.
  253. ^C. Corcoran; M. Rabinowitch (1937). “A Study of the Blood Lipoids and Blood Protein in Canadian Eastern Arctic Eskimos”. Biochem J. 31 (3): 343–348.PMC 1266943. PMID 16746345.
  254. ^Kang-Jey Ho; Belma Mikkelson; Lena A. Lewis; Sheldon A. Feldman; C. Bruce Taylor (1972). “Alaskan Arctic Eskimo: responses to a customary high fat diet”(PDF). Am J Clin Nutr. 25 (8): 737–745. Retrieved 2014-04-07.
  255. ^Dolson, Laura: The Most Common Low Carb Misconception, com: Low Carb Diets, 18 November 2006
  256. ^Nutrition: Carbohydrates, Women’s Health Channel, retrieved 13 March 2008
  257. ^Weickert MO, Pfeiffer AF (March 2008). “Metabolic effects of dietary fiber consumption and prevention of diabetes”. The Journal of Nutrition. 138 (3): 439–42.PMID 18287346.
  258. ^Teff, K. L.; Grudziak, J.; Townsend, R. R.; Dunn, T. N.; Grant, R. W.; Adams, S. H.; Keim, N. L.; Cummings, B. P.; et al. (2009). “Endocrine and Metabolic Effects of Consuming Fructose- and Glucose-Sweetened Beverages with Meals in Obese Men and Women: Influence of Insulin Resistance on Plasma Triglyceride Responses”.Journal of Clinical Endocrinology & Metabolism. 94 (5): 1562–1569.doi:1210/jc.2008-2192.
  259. ^Dolson, Laura: Vegetables on a Low-Carb Diet: The Best and Worst, com: Low Carb Diets, 3 March 2008
  260. ^Jennifer Warner: Fiber-Rich Fruits and Cereals Protect Heart, Web MD, 23 February 2004. Cites 2004 study in The Archives of Internal Medicine showing that fiber from cereals and fruits is more beneficial than fiber from vegetable sources.
  261. ^Kwon, O.; Eck, P.; Chen, S.; Corpe, C. P.; Lee, J.-H.; Kruhlak, M.; Levine, M. (2007). “Inhibition of the intestinal glucose transporter GLUT2 by flavonoids”. The FASEB Journal. 21 (2): 366–77. doi:1096/fj.06-6620com. PMID 17172639.
  262. ^Song, J; Kwon, O; Chen, S; Daruwala, R; Eck, P; Park, JB; Levine, M (2002). “Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and Glucose”. The Journal of Biological Chemistry. 277 (18): 15252–60.doi:1074/jbc.M110496200. PMID 11834736.
  263. ^Miller, Kenneth B.; Hurst, William Jeffery; Payne, Mark J.; Stuart, David A.; Apgar, Joan; Sweigart, Daniel S.; Ou, Boxin (2008). “Impact of Alkalization on the Antioxidant and Flavanol Content of Commercial Cocoa Powders”. Journal of Agricultural and Food Chemistry. 56 (18): 8527–33. doi:1021/jf801670p. PMID 18710243.
  264. ^Cordain, Loren: The Paleo Diet, pages 106–107, Wiley, 2002, 272 pages, ISBN 0-471-41390-9
  265. ^Gross LS, Li L, Ford ES, Liu S (May 2004). “Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment”. The American Journal of Clinical Nutrition. 79 (5): 774–9.PMID 15113714.
  266. ^Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF (April 2001). “Ketone bodies, potential therapeutic uses”. IUBMB Life. 51 (4): 241–7.doi:1080/152165401753311780. PMID 11569918.
  267. ^Sonnenburg, Erica D.; Sonnenburg, Justin L. (2014). “Starving our Microbial Self: The Deleterious Consequences of a Diet Deficient in Microbiota-Accessible Carbohydrates”. Cell Metabolism. 20: 779–786. doi:1016/j.cmet.2014.07.003.ISSN 1550-4131.
  268. ^Langkilde AM, Champ M, Andersson H (January 2002). “Effects of high-resistant-starch banana flour (RS(2)) on in vitro fermentation and the small-bowel excretion of energy, nutrients, and sterols: an ileostomy study”. Am. J. Clin. Nutr. 75 (1): 104–11.PMID 11756067. Retrieved 2014-07-17.
  269. ^  to:ab Bird AR, Brown IL, Topping DL (March 2000). “Starches, resistant starches, the gut microflora and human health”. Curr Issues Intest Microbiol. 1 (1): 25–37.PMID 11709851.
  270. ^Sajilata, M.G.; Singhal, Rekha S.; Kulkarni, Pushpa R. (2006). “Resistant Starch—A Review”. Comprehensive Reviews in Food Science and Food Safety. 5 (1): 1–17.doi:1111/j.1541-4337.2006.tb00076.x. ISSN 1541-4337.
  271. ^Birt DF, Boylston T, Hendrich S, et al. (November 2013). “Resistant starch: promise for improving human health”. Adv Nutr. 4 (6): 587–601.doi:3945/an.113.004325. PMC 3823506. PMID 24228189. Retrieved2014-07-18.
  272. ^Topping DL, Clifton PM (July 2001). “Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides”. Physiol. Rev. 81(3): 1031–64. PMID 11427691. Retrieved 2014-07-17.
  273. ^Brouns, Fred; Kettlitz, Bernd; Arrigoni, Eva (2002). “Resistant starch and “the butyrate revolution””. Trends in Food Science & Technology. 13 (8): 251–261.doi:1016/S0924-2244(02)00131-0. ISSN 0924-2244.
  274. ^Fuentes-Zaragoza, E.; Riquelme-Navarrete, M.J.; Sánchez-Zapata, E.; Pérez-Álvarez, J.A. (2010). “Resistant starch as functional ingredient: A review”. Food Research International. 43 (4): 931–942. doi:1016/j.foodres.2010.02.004.ISSN 0963-9969.
  275. ^Ahmed, R.; Segal, I.; Hassan, H. (2000). “Fermentation of dietary starch in humans”. The American Journal of Gastroenterology. 95 (4): 1017–1020.doi:1111/j.1572-0241.2000.01848.x. ISSN 0002-9270.
  276. ^Raben A, Tagliabue A, Christensen NJ, Madsen J, Holst JJ, Astrup A (October 1994). “Resistant starch: the effect on postprandial glycemia, hormonal response, and satiety”. Am. J. Clin. Nutr. 60 (4): 544–51. PMID 8092089. Retrieved 2014-07-17.
  277. ^Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN (September 2005).”Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism”. Am. J. Clin. Nutr. 82 (3): 559–67.PMID 16155268. Retrieved 2014-07-17.
  278. ^  to:ab Carbohydrates in human nutrition (Report of a Joint FAO/WHO Expert Consultation, Rome, Italy, 14–18 April 1997). FAO food and nutrition paper. 66.World Health Organization. 1998. ISBN 9251041148.
  279. ^Nugent A.P. (2005). “Health properties of resistant starch, British Nutrition Foundation”. Nutrition Bulletin. 30 (1): 27–54. doi:1111/j.1467-3010.2005.00481.x.
  280. ^National Research Council (2005). Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.National Academies Press. ISBN 0309085373.
  281. ^Joel Ceausu (26 November 2004). “CANADA: Low-carb products could be barred with new labelling rules”. just-food.com. Aroq Ltd. Retrieved 12 February 2014